WO2013018053A1 - Process for the preparation of epoxides as intermediates for the synthesis of nebivolol - Google Patents
Process for the preparation of epoxides as intermediates for the synthesis of nebivolol Download PDFInfo
- Publication number
- WO2013018053A1 WO2013018053A1 PCT/IB2012/053956 IB2012053956W WO2013018053A1 WO 2013018053 A1 WO2013018053 A1 WO 2013018053A1 IB 2012053956 W IB2012053956 W IB 2012053956W WO 2013018053 A1 WO2013018053 A1 WO 2013018053A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- epoxides
- process according
- nebivolol
- diols
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 229960000619 nebivolol Drugs 0.000 title claims abstract description 39
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 37
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 35
- 230000008569 process Effects 0.000 title claims abstract description 26
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title claims abstract description 25
- 239000000543 intermediate Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 7
- 150000002118 epoxides Chemical class 0.000 title claims 14
- 239000000203 mixture Substances 0.000 claims description 94
- 150000002009 diols Chemical class 0.000 claims description 89
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 45
- 239000000243 solution Substances 0.000 claims description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 32
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 27
- 150000002148 esters Chemical class 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 18
- 150000001414 amino alcohols Chemical class 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 9
- WFRBDWRZVBPBDO-UHFFFAOYSA-N 2-methyl-2-pentanol Chemical compound CCCC(C)(C)O WFRBDWRZVBPBDO-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000012279 sodium borohydride Substances 0.000 claims description 8
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 8
- FEINRNIWVDWBIG-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonyl-1h-imidazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1=NC=CN1 FEINRNIWVDWBIG-UHFFFAOYSA-N 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 150000002902 organometallic compounds Chemical class 0.000 claims description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000011065 in-situ storage Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 4
- JWEXHQAEWHKGCW-BIISKSHESA-N (R,S,S,S)-nebivolol hydrochloride Chemical compound Cl.C1CC2=CC(F)=CC=C2O[C@H]1[C@@H](O)CNC[C@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 JWEXHQAEWHKGCW-BIISKSHESA-N 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 238000005650 intramolecular substitution reaction Methods 0.000 claims description 3
- 229940068174 nebivolol hydrochloride Drugs 0.000 claims description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 2
- 238000003436 Schotten-Baumann reaction Methods 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 239000012448 Lithium borohydride Substances 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229910052792 caesium Inorganic materials 0.000 claims 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000002924 oxiranes Chemical class 0.000 abstract description 85
- GVZDIJGBXSDSEP-UHFFFAOYSA-N 6-fluoro-2-(oxiran-2-yl)-3,4-dihydro-2h-chromene Chemical compound C1CC2=CC(F)=CC=C2OC1C1CO1 GVZDIJGBXSDSEP-UHFFFAOYSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 29
- -1 6-fluoro-2- (oxiran-2-yl) chroman epoxides Chemical class 0.000 description 21
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- 238000003756 stirring Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 6
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000007070 tosylation reaction Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000003328 mesylation reaction Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ZNJANLXCXMVFFI-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound FC1=CC=C2OC(C(=O)O)CCC2=C1 ZNJANLXCXMVFFI-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- GCGMAEKAEXMJNG-FTNKSUMCSA-N (1s)-1-(6-fluoro-3,4-dihydro-2h-chromen-2-yl)ethane-1,2-diol Chemical compound FC1=CC=C2OC([C@@H](O)CO)CCC2=C1 GCGMAEKAEXMJNG-FTNKSUMCSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KOHIRBRYDXPAMZ-YHDSQAASSA-N (R,S,S,S)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@@H](O)CNC[C@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHDSQAASSA-N 0.000 description 1
- 0 *NC[C@@]([C@@](CCc1c2)Oc1ccc2F)O Chemical compound *NC[C@@]([C@@](CCc1c2)Oc1ccc2F)O 0.000 description 1
- UUNIOFWUJYBVGQ-UHFFFAOYSA-N 2-amino-4-(3,4-dimethoxyphenyl)-10-fluoro-4,5,6,7-tetrahydrobenzo[1,2]cyclohepta[6,7-d]pyran-3-carbonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1C(C#N)=C(N)OC2=C1CCCC1=CC=C(F)C=C12 UUNIOFWUJYBVGQ-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- USWINTIHFQKJTR-UHFFFAOYSA-N 3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=CC2=C1 USWINTIHFQKJTR-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- AADYIFLRRCYLRF-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromene Chemical compound O1CCCC2=CC(F)=CC=C21 AADYIFLRRCYLRF-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- XGEHECVTXHLTPD-KOLCDFICSA-N BNC[C@H]([C@H](CCc1c2)Oc1ccc2F)O Chemical compound BNC[C@H]([C@H](CCc1c2)Oc1ccc2F)O XGEHECVTXHLTPD-KOLCDFICSA-N 0.000 description 1
- GDOSOGICUVJQEX-LLVKDONJSA-N CCO[C@@H](CCc1c2)Oc1ccc2F Chemical compound CCO[C@@H](CCc1c2)Oc1ccc2F GDOSOGICUVJQEX-LLVKDONJSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- GVZDIJGBXSDSEP-QWRGUYRKSA-N Fc(cc1CC2)ccc1O[C@@H]2[C@H]1OC1 Chemical compound Fc(cc1CC2)ccc1O[C@@H]2[C@H]1OC1 GVZDIJGBXSDSEP-QWRGUYRKSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical group COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- RZRMSNYMSWJVPL-UHFFFAOYSA-N OCCC(CCc1c2)=[O]c1ccc2F Chemical compound OCCC(CCc1c2)=[O]c1ccc2F RZRMSNYMSWJVPL-UHFFFAOYSA-N 0.000 description 1
- YMWYHHYQTORXMJ-SNVBAGLBSA-N OCC[C@@H](CCc1c2)Oc1ccc2F Chemical compound OCC[C@@H](CCc1c2)Oc1ccc2F YMWYHHYQTORXMJ-SNVBAGLBSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- XLTYRVHHKJREDL-LLVKDONJSA-N ethyl (2R)-6-fluoro-3,4-dihydro-2H-chromene-2-carboxylate Chemical compound FC=1C=C2CC[C@@H](OC2=CC1)C(=O)OCC XLTYRVHHKJREDL-LLVKDONJSA-N 0.000 description 1
- XLTYRVHHKJREDL-NSHDSACASA-N ethyl (2s)-6-fluoro-3,4-dihydro-2h-chromene-2-carboxylate Chemical compound FC1=CC=C2O[C@H](C(=O)OCC)CCC2=C1 XLTYRVHHKJREDL-NSHDSACASA-N 0.000 description 1
- XLTYRVHHKJREDL-UHFFFAOYSA-N ethyl 6-fluoro-3,4-dihydro-2h-chromene-2-carboxylate Chemical compound FC1=CC=C2OC(C(=O)OCC)CCC2=C1 XLTYRVHHKJREDL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CURJNMSGPBXOGK-UHFFFAOYSA-N n',n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)N(C(C)C)CCN CURJNMSGPBXOGK-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 238000010653 organometallic reaction Methods 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 125000005537 sulfoxonium group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a novel process for the synthesis of 6-fluoro-2- (oxiran-2-yl) chroman epoxides (1) , intermediates for the synthesis of nebivolol.
- Nebivolol is a racemic mixture of the two enantiomers [2S [2R [R [R] ] ] ] a, ' - [ imino-bis (methylene)] bis [ 6-fluoro-chroman-2-methanol ] and [2R [2S [S [S] ] ] ] , '- [imino-bis (methylene)] bis [ 6-fluoro-chroman-2-methanol ] (Scheme 2 ) .
- the 6-fluorochroman-2-carboxylate ester (2) by treatment at temperatures lower than -90 °C with the organometallic compound LiCH 2 Br, followed by low- temperature quenching with an aqueous solution and by treatment with a reducing agent, generates the diol (3) which, through tosylation and intramolecular substitution, leads to the epoxide (1) without alteration of the starting diastereoisomeric composition.
- This method is applicable to a racemate ester (2) to obtain the mixture of epoxides (1) , or to an optically active ester to obtain the semichiral epoxides.
- x leaving group a. base; b. mCPBA.
- the aldehyde may be obtained by low-temperature reduction of the imidazolide of the corresponding acid or of the same ester (2) with diisobutyl aluminium hydride.
- the aldehyde is then converted into the epoxide (1) by reaction with sodium hydride and trimethyl sulfoxonium iodide in dimethylsulfoxide, as already described foregoing .
- the aldehyde of the chroman is not particularly stable and is prone to racemation when it is prepared in an optically active form.
- Tetrahedron (2000), 56, 6339-6344 a synthesis of the above-mentioned epoxides in chiral form is reported which, starting from 4-fluoro phenol, through a sequence rather rich in steps, provides the glycols of type (3) which are then transformed into epoxides via tosylates (Scheme 7 ) .
- a. allyl bromide, K 2 C0 3 ; b. 210°C, c. TBDMSCI; d. borane-dimethyl sulfide, H 2 0 2 , OH " ; d. Dess Martin; e. Ph 3 P CHC0 2 Et; f. DIBAL; g. TBAF; h. Sharpless oxidation followed by cyclization; i. PNB-OH, DEAD, TPP; I. NaOMe; m.TsCI, py; n. NaOMe.
- WO 2008/040528 Zach System reports the conversion of an ester of 6-fluoro-3, 4-dehydro-2H-chromen-2- carboxylate into 2-halo-l- ( 6-fluoro-3, 4-dehydro-2H- chromen-2-yl ethanone (alpha-haloketone) via sulfoxonium ylide; the reduction of the alpha-haloketone, followed by cyclization in the presence of a base, to yield the mixture of the four epoxide diastereoisomers (Scheme 8) .
- WO 2008/010022 (Zach System) reports a synthesis (Scheme 9) in which the acid deriving from ester (2) is reacted with dimedone to then produce in two steps the corresponding alpha-chloro or alpha-bromo ketone, which is reduced and cyclized to epoxide.
- the sequence is rather lengthy and toilsome.
- WO 2010/034927 reports always the preparation of alpha-halo ketones as epoxide precursors.
- the alpha-halo ketones are prepared as described in Scheme 10.
- the ester (2) is treated at low temperature with LiCH 2 Cl to obtain, after quenching with acetic acid, the corresponding alpha-chloro ketone which is then reduced to alpha-chloro alcohol and cyclized to epoxide.
- the alkyl 6- fluorochroman-2-carboxylate (2) for treatment at a temperature lower than -90 °C with the organometallic compound LiCf ⁇ Br, optionally generated in situ, followed by quenching, carried out always at a temperature lower than -90°C with an aqueous solution, followed by treatment with a reducing agent such as NaBH 4 , generates the diol (3) which, by tosylation and intramolecular nucleophilic substitution, generates the epoxide (1) without alteration of the starting diastereoisomeric composition .
- a reducing agent such as NaBH 4
- alpha hydroxy-ketone (4) is alpha hydroxy-ketone (4) , isolated and characterized by the present Inventors, which by reduction with NaBH 4 yields the diol (3) .
- object of the present invention is a process for the preparation of epoxides as intermediates in the synthesis of nebivolol, comprising:
- epoxides thus obtained can be used for the preparation of nebivolol according to methods already well-known in the art.
- This synthesis provides for the treatment of the mixture of epoxides (1) with benzylamine in a solvent represented by a sterically hindered alcohol, alone or in a mixture with an apolar solvent, to obtain a mixture of four compounds (9, 10, 11, and 12) , from which the pair 9/10 is separated from the pair 11/12 by crystallization or chromatography.
- a solvent represented by a sterically hindered alcohol alone or in a mixture with an apolar solvent
- the present synthesis gives rise to the semichiral epoxides, specifically to the RS/RR mixture or to the SS/SR mixture, depending on whether the starting ethyl carboxylate is the R isomer or the S isomer.
- nebivolol synthesis From the mixtures of semichiral epoxides it is possible to carry out nebivolol synthesis according to methods known in the art, e.g., the semichiral (RR + RS) and (SS + SR) epoxides are reacted separately with benzylamines under the conditions described in the foregoing, to obtain the separated compounds (9), (10), (11) and (12) . Then, the amine (9) is reacted with the epoxide (12) to obtain solely the enantiomer (15) , whereas the amine (10) is reacted with the epoxide (11) to obtain solely the enantiomer (13) .
- the two benzylated derivatives (13) and (15) of nebivolol are united in equal parts and subjected to catalytic hydrogenation in order to have nebivolol (Scheme 12) .
- This conversion provides the transformation of the ester (2) into the diol (3) via alpha-hydroxy ketone (4) .
- Alpha-hydroxy ketone (4) is obtained by treatment of (2) with LiCH2Br, at low temperatures and in an inert organic solvent, and subsequent quenching at low temperatures .
- the organometallic compound LiCH 2 Br may be preferentially obtained in situ by adding a BuLi solution to a solution containing the ester (2) and the CH 2 Br 2 in an inert organic solvent.
- the temperature is lower than - 90°C, preferentially comprised between -130°C e -95°, and even more preferentially between -105°C and -95°C.
- the solvent belongs to the family of hydrocarbons or of ethers, alone or in mixture, preferably tetrahydrofuran alone or in mixture.
- an aqueous solution is added; said solution may be neutral or acidic, but anyhow used in an amount such as to maintain the environment under alkalinity conditions, and preferably 0.1 M NaHSC>4, and temperature is let rise to values comprised between -50 and -10°C, preferably -30°C.
- a reducing agent (L1BH 4 , NaB3 ⁇ 4) , and preferentially NaBIHU, is added, and it is kept under stirring until complete disappearance of the alpha- hydroxy ketone intermediate (4) to obtain the diol (3) .
- An aspect of the present invention relates to the procedure from the enantiopure chroman ester (2) according to which: under the same conditions described for the racemate ester (2) , the ester (2) as R isomer or, alternatively, as S isomer, is reacted until providing a mixture of diols (5) comprised of RS + RR isomers
- Another characteristic aspect of the present invention is the procedure enabling purification of the diols (3) or of the semichiral mixtures (5) or (6) obtained with the preceding method.
- This procedure envisages the dissolution of the crude product, obtained from the synthesis of diols as described above, into an organic polar solvent, such as methanol, ethanol, acetonitrile, DMF, DMI, NMP, and preferentially methanol, and the subsequent washing of the solution thus obtained with a C5-C 10 alkane, immiscible with the former, and preferentially heptane.
- This washing enables to remove aliphatic apolar byproducts generated during the reaction with the organometallic compound, since the diol (3) or the corresponding mixtures of semichiral diols (5) and (6) are scarcely soluble in apolar organic solvents.
- Another characteristic aspect of the present invention is represented by the reaction of formation of the epoxides (1) , from the neighbouring diols (3) , conducted by tosylation or mesylation and subsequent intramolecular nucleophilic substitution, two-stage or one-pot, carried out so as not to alter the initial diastereomeric ratio.
- a further alternative is the treatment of a solution of the diol (3) into an organic solvent non-miscible with water and containing an organic base, preferentially diisopropylethylamine, cooled and maintained at a temperature lower than 25°C, preferentially lower than 4°C, with a solution of tosyl chloride in organic solvent, followed by addition of a 50% aqueous NaOH solution .
- the diol (3) (RS+SR:RR+SS mixture in a 1:1 ratio) obtained from the racemate ester (2) by the organometallic reaction described, it is obtained, by tosylation or mesylation and base-catalyzed nucleophilic intramolecular substitution according to any one of the above-described methods, the mixture (RS+SR : RR+SS ) of epoxides (1) in a 1:1 diastereoisomeric ratio.
- a further object of the present invention is the synthesis of nebivolol in the form of racemic mixture of the two enantiomers [2S [2R [R [R] ] ] ] a, a' - [ imino-bis (methylene)] bis [ 6-fluoro-chroman-2-methanol ] and
- NebivoloL (SRRR + RSSS) comprising the following steps:
- racemate ester (2) is reacted with benzylamine in a solvent represented by a sterically hindered alcohol selected from tert-BuOH, 2-methyl-2- butanol, 2-methyl-2-pentanol, used alone or in mixture with an apolar solvent, preferably cyclohexane, to obtain a mixture of the four compounds 9, 10, 11 and 12, from which the pair 9/10 is separated from the pair 11/12;
- a solvent represented by a sterically hindered alcohol selected from tert-BuOH, 2-methyl-2- butanol, 2-methyl-2-pentanol, used alone or in mixture with an apolar solvent, preferably cyclohexane
- the protecting group benzyl is removed from mixture 13 and 15, and the hydrochloride salt is optionally subsequently formed, to obtain the final product Nebivolol or Nebivolol hydrochloride.
- Another aspect of the present invention consists in the synthesis of nebivolol, comprising the following steps :
- the product was recovered by cutting of the corresponding silica strip, subsequent washing with acetonitrile followed by solvent removal .
- Example 6 Synthesis of epoxides (1) from diols (3) Use of NaH and DMSO in methyl t-butyl eter and TsCl To a NaH suspension (2.70 g, 0.07 mol, 4 eq) in MTBE (75 mL) , anhydrous DMSO (10 mL, 0.14 mol, 8 eq) was added under N 2 atmosphere at 50°C. After 5-10 min, a solution of the diols (3) (5.00 g, 0.017 mol) in MTBE (75 mL) was added and the mixture was stirred at 50°C for 1 hour.
- a biphasic system comprised of the diols (6, SR/SS, diastereoisomeric ratio: 1.1/1.0) (100 mg, 0.40 mmol) in DCM (2.0 mL, 20 vol) and of an aqueous solution of 50% NaOH (0.5 mL, 5 vol), was maintained under vigorous stirring for 1 hour.
- a solution of tosyl imidazole (115.6 mg, 0.52 mmol, 1.3 eq) in DCM (2.5 mL, 25 vol) was added dropwise to the suspension in 15 min at room temperature.
- the mixture was poured in water (2 mL) , organic phase was separated, washed with water and dried over a 2 S0 4 . Solvent was removed under reduced pressure, giving a viscous residue.
- HPLC analysis showed the presence of diastereoisomeric epoxides (8) ( 73% purity) in a 1.1/1.0 ratio.
- the mixture was left under stirring at 4°C and, at the end of the reaction (12 hours), was treated with 2- (diisopropylamino) ethylamine (2.0 mL, 11.43 mmol, 0.2 eq) for 15 minutes, then shaken with 0.1 M aHS0 4 and water.
- the mixture can be treated with 8.5 g of (aminomethyl) polystyrene resin (1.5 mmol/g) for about 1 hour and then filtered.
- 50% aqueous NaOH (30 mL) was added, and it was vigorously stirred to completion of the epoxides formation reaction (30 min) .
- EXAMPLE 10 Kinetic resolution on the mixture of (SS + SR) epoxides .
- EXAMPLE 12 Synthesis of (RRRS) d-benzyl nebivolol
- the compound (SR)-2- benzylamino -l-(6- fluorochroman-2-yl (10), ethanol and the epoxide (11, RR) were treated as in Example 11, to obtain d-benzyl nebivolol .
- the compound d, l-benzyl nebivolol (2.0 g, 4.0 mmol) was dissolved in methanol (160 mL) along with 20% (1% b/w) Pd(OH) 2 /C. The mixture was maintained under stirring, under hydrogen atmosphere. At the end of the reaction the catalyst was filtered on a porous septum, and concentrated HC1 (0.52 mL) was added to the filtrate. The solution was concentrated under reduced pressure and the obtained residue was heat-treated with absolute ethanol (20 mL) . The obtained solid was filtered and dried under vacuum (1.7 g) .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to a novel process of synthesis of epoxides, 6-fluoro-2- (oxiran-2-yl) chroman (Figure 1), intermediates for the synthesis of nebivolol, depicted in Scheme (1), enabling to obtain the above- mentioned epoxides in a racemic or semichiral form.
Description
PROCESS FOR THE PREPARATION OF EPOXIDES AS INTERMEDIATES FOR THE SYNTHESIS OF NEBIVOLOL
FIELD OF THE INVENTION
The present invention relates to a novel process for the synthesis of 6-fluoro-2- (oxiran-2-yl) chroman epoxides (1) , intermediates for the synthesis of nebivolol.
Nebivolol is a racemic mixture of the two enantiomers [2S [2R [R [R] ] ] ] a, ' - [ imino-bis (methylene)] bis [ 6-fluoro-chroman-2-methanol ] and [2R [2S [S [S] ] ] ] , '- [imino-bis (methylene)] bis [ 6-fluoro-chroman-2-methanol ] (Scheme 2 ) .
d- nebivolol l-nebivolol
(SRRR) (RSSS)
Nebivolol
Scheme (2)
The 6-fluorochroman-2-carboxylate ester (2) , by treatment at temperatures lower than -90 °C with the organometallic compound LiCH2Br, followed by low- temperature quenching with an aqueous solution and by treatment with a reducing agent, generates the diol (3) which, through tosylation and intramolecular substitution, leads to the epoxide (1) without alteration of the starting diastereoisomeric composition.
This method is applicable to a racemate ester (2) to obtain the mixture of epoxides (1) , or to an optically active ester to obtain the semichiral epoxides.
STATE OF THE ART
US Patent No. 4,654,362 (and its counterpart EP 0145067) reports the reduction of the ester (2) to alcohol with Red-Al (NaAlH2 (OC2H4OCH3) 2) , followed by
oxidation to obtain the corresponding aldehyde, and by treatment with (Me3)3SO+I~ to have the epoxides (1) (Scheme 3) .
The same fundamental synthetic scheme, with ameliorative modifications in terms of yield and purity, is reported in WO 2010/089764 (Dr. Reddy's).
a. Red-AI; b. (COCI)2, DMSO, CH2CI2; c. (CH3)3SO+ I", NaH, DMSO.
Scheme (3)
Always in US No. 4,654,362, as generic possibilities for this class of compounds, are reported that of obtaining the epoxides (1) by elimination from alpha- substituted alcohols with a good leaving group (X) or by epoxidation of the corresponding olefin with base and metachloroperbenzoic acid (Scheme 4).
x= leaving group a. base; b. mCPBA.
Scheme (4)
Other methods for preparing the aldehyde and then the epoxides of type (1) are reported in Scheme 5.
The aldehyde may be obtained by low-temperature reduction of the imidazolide of the corresponding acid or of the same ester (2) with diisobutyl aluminium hydride. The aldehyde is then converted into the epoxide (1) by reaction with sodium hydride and trimethyl sulfoxonium
iodide in dimethylsulfoxide, as already described foregoing .
a. DIBAH, -80°C; b. 1. CDI, THF, rt; 2. DIBAH, -70°C; c. (CH3)3SO<+> I», NaH, DMSO
Scheme (5)
The method of Scheme (5) , envisaging the reduction of the ester to aldehyde, is explicitly reported for the 6-fluoro derivative by EP 0334429 using the chiral ester, and is directed to prepare separately the single optical isomers (R,S;S,S) and (S,R;R,R) of nebivolol. In this instance, 6-fluoro-chroman carboxylic acid is resolved into single enantiomers by treatment with (+) - dehydroabiethylamine . Said enantiomers are separately converted into their corresponding epoxides, resulting in mixtures of two diastereoisomers . The following synthetic scheme (Scheme 6) describes the conversion of the R-acid.
a. carbonyl diimidazole, then DIBAL; b. Me3S0, tBuOK, DMSO
Scheme (6)
The aldehyde of the chroman is not particularly stable and is prone to racemation when it is prepared in an optically active form.
In Tetrahedron (2000), 56, 6339-6344 a synthesis of the above-mentioned epoxides in chiral form is reported which, starting from 4-fluoro phenol, through a sequence rather rich in steps, provides the glycols of type (3) which are then transformed into epoxides via tosylates (Scheme 7 ) .
a. allyl bromide, K2C03; b. 210°C, c. TBDMSCI; d. borane-dimethyl sulfide, H202, OH"; d. Dess Martin; e. Ph3P=CHC02Et; f. DIBAL; g. TBAF; h. Sharpless oxidation followed by cyclization; i. PNB-OH, DEAD, TPP; I. NaOMe; m.TsCI, py; n. NaOMe.
Scheme ( 7 )
This method, despite allowing to obtain the epoxides in an optically pure form, is very lengthy and toilsome.
WO 2008/040528 (Zach System) reports the conversion of an ester of 6-fluoro-3, 4-dehydro-2H-chromen-2- carboxylate into 2-halo-l- ( 6-fluoro-3, 4-dehydro-2H- chromen-2-yl ethanone (alpha-haloketone) via sulfoxonium ylide; the reduction of the alpha-haloketone, followed by cyclization in the presence of a base, to yield the mixture of the four epoxide diastereoisomers (Scheme 8) .
a. Me3SI, tBuOK, THF; b. LiCI, MeS03H
Scheme (8)
WO 2008/010022 (Zach System) reports a synthesis (Scheme 9) in which the acid deriving from ester (2) is reacted with dimedone to then produce in two steps the corresponding alpha-chloro or alpha-bromo ketone, which is reduced and cyclized to epoxide. The sequence is rather lengthy and toilsome.
Scheme (9)
WO 2010/034927 (Zach System) reports always the preparation of alpha-halo ketones as epoxide precursors. In this instance, the alpha-halo ketones are prepared as described in Scheme 10.
The ester (2) is treated at low temperature with LiCH2Cl to obtain, after quenching with acetic acid, the corresponding alpha-chloro ketone which is then reduced to alpha-chloro alcohol and cyclized to epoxide.
a. BuLi, CHBrCI, -80°C, then AcOH; b. NaBH4, EtOH, 0°C; c. i-PrOH, NaOH
Scheme (10)
This method, though being rather short, entails the drawback of not eliminating the apolar reaction byproducts deriving from the organometallic species used, until the end stage of epoxide. These byproducts are of aliphatic type, numerous, of slightly different nature with each other, and are not visible under UV. For these reasons, they are difficult to quantify. In addition, some are bromo- or chloro-alkyls which may then invalidate the yields of the reactions subsequently used for the preparation of nebivolol, as well as the purity of products obtained. It is not possible to carry out a purification of the intermediate product, the aloalcohol, by extraction or partition.
SUMMARY OF THE INVENTION
We have now, surprisingly, found a more efficient process of synthesis of epoxide intermediates (1) , racemates or semichiral ones, which is summarized in Scheme 1. Such a process allows to eliminate the drawbacks already highlighted for the previously known synthesis pathways, i.e.:
• length and complexity of synthetic pathways
• need of chromatographic purifications to eliminate apolar aliphatic residues of secondary reactions yielded by reagents used.
According to this process, the alkyl 6- fluorochroman-2-carboxylate (2) , for treatment at a temperature lower than -90 °C with the organometallic compound LiCf^Br, optionally generated in situ, followed by quenching, carried out always at a temperature lower
than -90°C with an aqueous solution, followed by treatment with a reducing agent such as NaBH4, generates the diol (3) which, by tosylation and intramolecular nucleophilic substitution, generates the epoxide (1) without alteration of the starting diastereoisomeric composition .
In a single step we go from the ester (2) to the diol (3) , from the crude reaction material of which the apolar aliphatic species produced during the reaction can be eliminated by simple washings: a solution of the crude material in a polar organic solvent is treated with an apolar solvent immiscible with the former, in which diols are scarcely soluble. This method therefore proves more suitable for a large-scale synthesis process.
Such a synthesis allows to obtain the above- mentioned epoxides (1) in a racemate or semichiral form, where by "racemate form" a mixture of the 4 epoxides indicated in Figure 1 is meant, and by "semichiral form" a mixture of only two diastereomeric epoxides of RS + RR or SR + SS type is meant, in which the asymmetric center on the six-member ring of the pyrane has the same stereochemistry .
The mechanism of such a reaction is not clear, but it ought not be the classic one reported in the literature for the treatment of an ester with an organometallic compound, and preferably with an organolithium. In that case one would expect the intermediate initially formed, of type:
What instead is observed after low-temperature
(lower than -90°C) quenching with a 0.1M NaHSC>4 solution is alpha hydroxy-ketone (4) , isolated and characterized by the present Inventors, which by reduction with NaBH4 yields the diol (3) .
(4)
Therefore, object of the present invention is a process for the preparation of epoxides as intermediates in the synthesis of nebivolol, comprising:
a. synthesizing the diols of type (3) starting from a chroman ester (2) , both racemate and optically active, for treatment with LiCH2Br at a temperature lower than -90 °C, aqueous quenching at a low temperature and subsequent treatment with a reducing agent such as NaBH4;
b. purifying the diols thus obtained by partitioning between a polar organic solvent and an apolar solvent, immiscible with each other;
c. transforming the diols (3) into epoxides (1) , by tosylation or mesylation, and intramolecular nucleophilic substitution without alteration of the ratio between diastereoisomers .
The epoxides thus obtained can be used for the preparation of nebivolol according to methods already well-known in the art.
By way of example, the synthesis described in Scheme 11 can be used to obtain nebivolol (WO2011/098474) .
Nebivolol (SRRR + RSSS)
Scheme 11
This synthesis provides for the treatment of the mixture of epoxides (1) with benzylamine in a solvent represented by a sterically hindered alcohol, alone or in a mixture with an apolar solvent, to obtain a mixture of four compounds (9, 10, 11, and 12) , from which the pair 9/10 is separated from the pair 11/12 by crystallization or chromatography. There follows the reaction of amines 9/10 with the epoxides 11/12 to obtain a mixture of four
compounds (13, 14, 15 and 16) . From this mixture, the compounds 13 and 15 (RSSS + SRRR) in mixture are separated from 14 and 16 by fractionated crystallization with a suitable solvent. A reaction of catalytic hydrogenation of the mixture 13/15 provides nebivolol.
Methods for separating the enantiomers of an alkyl alchil 6-fluorochroman-2-carboxylate are known, for instance as described in EP334429 by amide formation with (+) -dehydroabiethylamine, or, as reported in the Italian Patent Application RM2010A000622 of 11/30/2010, by enzymatic hydrolysis by a fungal esterase.
When the starting alkyl 6-fluorochroman-2- carboxylate (2) is a definite isomer, the present synthesis gives rise to the semichiral epoxides, specifically to the RS/RR mixture or to the SS/SR mixture, depending on whether the starting ethyl carboxylate is the R isomer or the S isomer.
From the mixtures of semichiral epoxides it is possible to carry out nebivolol synthesis according to methods known in the art, e.g., the semichiral (RR + RS) and (SS + SR) epoxides are reacted separately with benzylamines under the conditions described in the foregoing, to obtain the separated compounds (9), (10), (11) and (12) . Then, the amine (9) is reacted with the epoxide (12) to obtain solely the enantiomer (15) , whereas the amine (10) is reacted with the epoxide (11) to obtain solely the enantiomer (13) . The two benzylated derivatives (13) and (15) of nebivolol are united in equal parts and subjected to catalytic hydrogenation in order to have nebivolol (Scheme 12) .
DETAILED DESCRIPTION OF THE INVENTION
(1) are obtained with the method described in Scheme 1 from an ester (2) of 6-fluorochroman 2-carboxyl acid, both in a racemic mixture and as an isolated enantiomer, wherein R is a C1-C6 alkyl group, preferentially an ethyl group .
(2)
This conversion provides the transformation of the ester (2) into the diol (3) via alpha-hydroxy ketone (4) .
Alpha-hydroxy ketone (4) is obtained by treatment of (2) with LiCH2Br, at low temperatures and in an inert organic solvent, and subsequent quenching at low temperatures .
The organometallic compound LiCH2Br may be preferentially obtained in situ by adding a BuLi solution to a solution containing the ester (2) and the CH2Br2 in an inert organic solvent. The temperature is lower than - 90°C, preferentially comprised between -130°C e -95°, and even more preferentially between -105°C and -95°C.
The solvent belongs to the family of hydrocarbons or of ethers, alone or in mixture, preferably tetrahydrofuran alone or in mixture.
At completion of the reaction, keeping the mixture at the initial temperature, an aqueous solution is added; said solution may be neutral or acidic, but anyhow used in an amount such as to maintain the environment under alkalinity conditions, and preferably 0.1 M NaHSC>4, and temperature is let rise to values comprised between -50 and -10°C, preferably -30°C.
Then, a reducing agent (L1BH4, NaB¾) , and preferentially NaBIHU, is added, and it is kept under stirring until complete disappearance of the alpha- hydroxy ketone intermediate (4) to obtain the diol (3) .
An aspect of the present invention relates to the procedure from the enantiopure chroman ester (2) according to which: under the same conditions described for the racemate ester (2) , the ester (2) as R isomer or, alternatively, as S isomer, is reacted until providing a mixture of diols (5) comprised of RS + RR isomers
Another characteristic aspect of the present invention is the procedure enabling purification of the diols (3) or of the semichiral mixtures (5) or (6) obtained with the preceding method. This procedure envisages the dissolution of the crude product, obtained from the synthesis of diols as described above, into an organic polar solvent, such as methanol, ethanol, acetonitrile, DMF, DMI, NMP, and preferentially methanol, and the subsequent washing of the solution thus obtained with a C5-C10 alkane, immiscible with the former, and preferentially heptane. This washing enables to remove aliphatic apolar byproducts generated during the reaction with the organometallic compound, since the diol (3) or the corresponding mixtures of semichiral diols (5) and (6) are scarcely soluble in apolar organic solvents.
Another characteristic aspect of the present invention is represented by the reaction of formation of the epoxides (1) , from the neighbouring diols (3) , conducted by tosylation or mesylation and subsequent intramolecular nucleophilic substitution, two-stage or one-pot, carried out so as not to alter the initial diastereomeric ratio.
In this case it has surprisingly been found that treating the diol (3) with a base (selected from LiH, NaH, KH, tBuOK and preferentially NaH) , in an organic solvent (selected from DMF, DMSO, NMP (N- methylpyrrolidone) and DMI (dimethylimidazolidone) , preferentially DMF, and leaving the system under stirring for times higher than 1 hour, followed by addition of a mesylating or tosylating agent such as tosyl chloride, tosyl imidazole or mesyl chloride, and preferably tosyl chloride, results in the conversion in situ into epoxide without alteration of the initial ratio between the diastereoisomers .
Alternatively, it has surprisingly been discovered that by treating the diol (3) with a preformed solution of DMSO and NaH, or of imidazole and NaH in an organic solvent, followed by addition of a tosylating agent, selected from tosyl chloride or tosyl imidazole, preferably tosyl chloride, the conversion in situ into epoxide is obtained without alteration of the initial ratio between the diastereoisomers. Alternatively, the same result is obtained by treatment of the diols dissolved into an organic solvent non-miscible with water, with a tosylating agent selected from tosyl chloride or tosyl imidazole, preferably tosyl chloride, under Schotten-Baumann conditions.
A further alternative is the treatment of a solution of the diol (3) into an organic solvent non-miscible with water and containing an organic base, preferentially diisopropylethylamine, cooled and maintained at a temperature lower than 25°C, preferentially lower than 4°C, with a solution of tosyl chloride in organic solvent, followed by addition of a 50% aqueous NaOH solution .
Likewise, it has been demonstrated and is therefore an object of the present invention that, treating with the hereto-described methods the ,semichiral' mixture of
RS + RR diols (5) or, alternatively, the ,semichiral' mixture of SR + SS diols (6), yields the ,semichiral' mixture of RS + RR epoxides (7),
( RS) (RR)
(7) or, alternatively, the ,semichiral' mixture of SR + SS epoxides (8)
(8) without alteration of the diastereoisomeric ratios.
By way of a non-limiting example, starting from the diol (3) (RS+SR:RR+SS mixture in a 1:1 ratio) obtained from the racemate ester (2) by the organometallic reaction described, it is obtained, by tosylation or mesylation and base-catalyzed nucleophilic intramolecular substitution according to any one of the above-described methods, the mixture (RS+SR : RR+SS ) of epoxides (1) in a 1:1 diastereoisomeric ratio.
A further object of the present invention is the synthesis of nebivolol in the form of racemic mixture of the two enantiomers [2S [2R [R [R] ] ] ] a, a' - [ imino-bis (methylene)] bis [ 6-fluoro-chroman-2-methanol ] and
[2R [2S [S [S] ] ] ] a, ' -[ imino-bis (methylene)] bis [ 6-fluoro- chroman-2-methanol ] , having the following formulas
NebivoloL (SRRR + RSSS) comprising the following steps:
(1 )
obtained according to one of the methods described hereto starting from the racemate ester (2) , is reacted with benzylamine in a solvent represented by a sterically hindered alcohol selected from tert-BuOH, 2-methyl-2- butanol, 2-methyl-2-pentanol, used alone or in mixture with an apolar solvent, preferably cyclohexane, to obtain a mixture of the four compounds 9, 10, 11 and 12, from which the pair 9/10 is separated from the pair 11/12;
9 10 11 12 b) the amines 9 and 10, in mixture, are reacted with the pair of epoxides 11 and 12, in mixture, to obtain a mixture of four compounds (13, 14, 15 and 16) ;
c) the compounds 13 and 15 (RSSS + SRRR) , in mixture, are separated from 14 and 16 by fractionated crystallization from 2-methyl-2-butanol, and subsequently from an ethyl acetate/cyclohexane mixture,
d) the protecting group benzyl is removed from mixture 13 and 15, and the hydrochloride salt is optionally subsequently formed, to obtain the final product Nebivolol or Nebivolol hydrochloride.
Another aspect of the present invention consists in the synthesis of nebivolol, comprising the following steps :
a) kinetically resolving the ,semichiral' mixture of epoxides (7), and/or separately the ,semichiral' mixture of epoxides (8) , obtained according to the above-described methods starting respectively from the R or S chroman ester, by reacting them with benzylamine in a sterically hindered alcohol selected from tert-BuOH, 2-methyl-2-butanol, 2- methyl-2-pentanol, to obtain the compounds (9) and
(11) and/or respectively the compounds (10) and
(12) .
b) reacting the amino alcohol (9) with the epoxide (12) to obtain the 1-benzyl nebivolol (15) and/or the amino alcohol (10) with the epoxide (11) , to obtain the d-benzyl nebivolol (13)
c) removing the protecting group benzyl with forming of D- and/or L-nebivolol.
EXAMPLES
EXAMPLE 1: Synthesis of
1- (6-fluorochroman-2-yl) ethane-1 , 2-diol racemate diols
To a solution of racemate ethyl 6-fluorochroman-2- carboxylate (2.2 g, 10 mmol) and dibromomethane (1.35 mL) in anhydrous THF (40 mL) cooled to -100°C under nitrogen atmosphere, a solution of 1.6M MeLi in diethyl eter (11.2 mL) , cooled beforehand to -78°C, was added dropwise, in a time of about 30 min. Stirring was maintained at -100°C for about 1.0 h in total, until disappearance of ester substrate (TLC control). Then, a 0. IN NaHS04 solution (5 mL) was added at the same temperature. At the end of the addition the temperature was slowly brought to -30/-20°C and the mixture stirred for 30 min. Then, NaBH4 (0.3 g) was added and the resulting mixture mixed, after having removed the cooling bath, until complete reduction of the intermediate alpha-hydroxy ketone to diol (about 0.5 h) . IN NaHSC>4 was added to the mixture up to pH 5, the organic phase was separated and the aqueous phase extracted with EtOAc. The reunited organic extracts were washed with water, dried over Na2SC>4, filtered and concentrated at reduced pressure to obtain a yellow and viscous fluid (2.05 g) . HPLC analysis indicated a 97% purity of the two diastereoisomeric pairs of diols (in a substantially 1:1 ratio).
For characterization purposes, the two diastereoisomeric pairs of diols were separated by flash chromatography on silica (eluents EtOAc/petroleum ether
1:1).
(RS/SR) isomer
1H NMR (400 MHz, DMSO-d6) δ 6.98-6.82 (m, 2H) ; 6.75- 6.67 (m, 1H) , 4.92-4.90 (d, 1H, J = 6.0 Hz); 4.57 (t, 1H, J = 6.0 Hz); 3.95-3.88 (m, 1H) ; 3.60-3.50 (m, 2H) ; 3.50- 3.40 (m, 1H) ; 2.80-2.60 (m, 2H) ; 2.10-1.98 (m, 1H) ; 1.76- 1.63 (m, 1H) .
(SS/RR) isomer:
1H NMR (400 MHz, DMSO-d6) δ 6.98-6.80 (m, 2H) ; 6.75- 6.67 (m, 1H) , 4.80-4.76 (d, 1H, J = 6.0 Hz); 4.60 (t, 1H, J = 6.0 Hz); 4.00-3.94 (d, 1H, J = 14.0 Hz); 3.60-3.50 (m, 2H) ; 3.50-3.40 (m, 1H) ; 2.90-2.70 (m, 2H) ; 1.95-1.85 (m, 1H) ; 1.85-1.70 (m, 1H) .
The configuration of the two diastereoisomeric pairs of diols was attributed on the basis of the pair of enantiomeric epoxides produced by each of them.
EXAMPLE 2: Synthesis of
(S) -1- (6-fluorochroman-2-yl) ethane-1 , 2-diol
semichiral diols
To a solution of (S) -ethyl 6-fluorochroman-2- carboxylate) (18 g, 80.3 mmol) and dibromomethane (12.6 mL) in anhydrous THF (360 mL) cooled to -100°C under nitrogen atmosphere, a solution of 1.6M BuLi in hexane (101 mL) , cooled beforehand to -78°C, was added dropwise, in a time of 30 min. Stirring was maintained at -100°C for 1.5 h in total, until disappearance of the ester substrate (TLC control). Then, a 0. IN NaHS04 solution (40 mL) was added at the same temperature. At the end of the addition, temperature was slowly brought to -30/-20°C and it was stirred for 30-50 min. Then, NaBH4 (2.5 g) was added and the resulting mixture mixed until complete
reduction of the intermediate alpha-hydroxy ketone to diol (about 0.5 h) . IN NaHSC>4 was added to the mixture, up to pH 5, the organic phase was separated and the aqueous phase extracted with EtOAc. The reunited organic extracts were washed with water, dried over Na2SC>4, filtered and concentrated under reduced pressure to obtain a yellow and viscous fluid (18 g) . HPLC analysis showed a 1.1:1.0 ratio of the two (SR:SS) diastereoisomeric diols (6) .
Analogously to what described in example 2, the (RS:RR) diols 5 were obtained starting from (R) -ethyl 6- fluorochroman-2-carboxylate) .
Example 3 : diol purification
The residue containing the diols from Example 2 (18 g) was dissolved in CH3OH (2 volumes) . The resulting solution was shaken with heptane (10 volumes) . After phase separation, the methanol solution was concentrated under reduced pressure, obtaining a viscous residue (15 g) . 1H-NMR analysis indicated the absence of signals related to aliphatic impurities produced in the reaction of formation of the same diols. Following this purification step, the ratio of the two (RS:SS) diastereoisomeric diols remained unchanged.
Example 4: Isolation and characterization of intermediate alpha-hydroxy ketone
In order to demonstrate a possible reaction mechanism for the reaction described in Examples 1 and 2, the Inventors tried to isolate the intermediate alpha- hydroxy ketone (4) of the synthesis of RS:RR diols described by analogy
(4)
The reaction solution, still at -20°C after
quenching with NaHSC>4 and before addition of the reducing agent, was quickly deposited on a 2.5 mm-thick preparative silica plate and run using EtOAc/hexane 1:1 as eluent; Rf = 0.4, UV detection. The product was recovered by cutting of the corresponding silica strip, subsequent washing with acetonitrile followed by solvent removal .
1H NMR (400 MHz, CD3CN) δ 6.95-6.70 (m, 3H) ; 4.75- 4.70 (m, 1H) ; 4.60-4.38 (AB system, 2H, J = 17 Hz); 2.90- 2.60 (m, 2H) ; 2.20-2.00 (m, 1H) ; 1.90-1.60 (m, 1H) .
Alpha-hydroxy ketone (4) reduction with aBH4 produces the pair of diols RS:RR.
Example 5: Synthesis of epoxides (1) from diols (3)
Use of NaH and tosyl chloride in DMF.
To a solution of diols obtained according to Example 1 in a 1.1/1.0 diastereoisomeric ratio (200 mg, 0.80 mmol) in anhydrous DMF (6 mL, 30 volumes) NaH (48 mg, 2.0 mmol, 2.5 eq) was added. The mixture was left to equilibrate (1 hour), then tosyl chloride (305 mg, 1.60 mmol, 2 eq) was added. At the end of the reaction (8 hours), the mixture was diluted with MTBE (15 mL) and treated with 1M NaHSC^ (10 mL) . The organic phase was shaken with H20, dried over Na2SC>4 and concentrated to dryness, giving a viscous residue. HPLC analysis showed the presence of epoxides (1) (75% purity) in a 1.1/1.0 diastereoisomeric ratio.
Example 6: Synthesis of epoxides (1) from diols (3) Use of NaH and DMSO in methyl t-butyl eter and TsCl To a NaH suspension (2.70 g, 0.07 mol, 4 eq) in MTBE (75 mL) , anhydrous DMSO (10 mL, 0.14 mol, 8 eq) was added under N2 atmosphere at 50°C. After 5-10 min, a solution of the diols (3) (5.00 g, 0.017 mol) in MTBE (75 mL) was added and the mixture was stirred at 50°C for 1 hour. After this period, a solution of tosyl chloride (5.00 g, 0.026 mol, 1.5 eq) in MTBE (50 mL) was added dropwise and the mixture was maintained under stirring for 1 hour,
controlling the pattern by HPLC. At the end of the reaction the mixture was filtered, the filtrate washed with MTBE (50 mL x 2) and the reunited filtrates washed with NaHS04 1M (100 mL) , NaHC03 (2x50 mL) , and water (50 mL) and dried over Na2SC>4. Solvent was removed under reduced pressure to yield a viscous residue (yield: 90%, HPLC purity: 95.5%, diastereomeric ratio between epoxides: unchanged) .
Example 7: Synthesis of epoxides (1) from diols (3)
Use of NaH and imidazole
To a suspension of imidazole (190.6 mg, 2.80 mmol, 3.5 eq) and NaH (58 mg, 2.4 mmol, 3.0 eq) in a solvent such as DMF, DCM, THF, MTBE (3 mL) left under stirring for 10-15 min, the diols (200 mg, 0.80 mmol) (diastereoisomeric ratio: 1.0:1.0) dissolved in the solvent used (3 mL) were added, and after about 10 min tosyl chloride (213 mg, 1.10 mmol, 1.4 eq) was added. At the end of the reaction (2-3 hours) , the mixture was diluted with MTBE (15 mL) and treated with 1M NaHS04 (10 mL) . Organic phase was shaken with ¾0, dried over a2S04 and concentrated to dryness, giving a viscous residue. HPLC analysis showed the presence of diastereoisomeric epoxides in a 1.0/1.0 ratio (purity: 90%).
Example 8: Synthesis of epoxides (8) from diols (6)
Use of Schotten Baumann conditions
A biphasic system comprised of the diols (6, SR/SS, diastereoisomeric ratio: 1.1/1.0) (100 mg, 0.40 mmol) in DCM (2.0 mL, 20 vol) and of an aqueous solution of 50% NaOH (0.5 mL, 5 vol), was maintained under vigorous stirring for 1 hour. A solution of tosyl imidazole (115.6 mg, 0.52 mmol, 1.3 eq) in DCM (2.5 mL, 25 vol) was added dropwise to the suspension in 15 min at room temperature. At the end of the reaction (14 hours) the mixture was poured in water (2 mL) , organic phase was separated, washed with water and dried over a2S04. Solvent was removed under reduced pressure, giving a viscous residue.
HPLC analysis showed the presence of diastereoisomeric epoxides (8) ( 73% purity) in a 1.1/1.0 ratio.
Example 9: Synthesis of epoxides (8) from diols (6)
Use of diisopropylethylamine and tosyl chloride at low temperature
To a solution containing the SR/SS diols (10.15 g, 47.87 mmol) (1.1/1.0), diisopropylethylamine (10.65 mL, 61.11 mmol, 1.3 eq) and dimethylaminopyridine (0.17 g, 1.43 mmol, 0.03 eq) in DCM (250 mL) , tosyl chloride (10.9 g, 57.17 mmol, 1.2 eq) was added, at 0°C. The mixture was left under stirring at 4°C and, at the end of the reaction (12 hours), was treated with 2- (diisopropylamino) ethylamine (2.0 mL, 11.43 mmol, 0.2 eq) for 15 minutes, then shaken with 0.1 M aHS04 and water. Alternatively, the mixture can be treated with 8.5 g of (aminomethyl) polystyrene resin (1.5 mmol/g) for about 1 hour and then filtered. To the separated organic phase 50% aqueous NaOH (30 mL) was added, and it was vigorously stirred to completion of the epoxides formation reaction (30 min) . The mixture was diluted with water and the organic phase separated, it was washed with 1 M NaHS04, with water and finally dried over Na2SC>4. The solvent was removed under reduced pressure, giving a viscous residue (11 g, yield: 95%, diastereoisomeric ratio of the epoxides (8): 1.1/1.0).
EXAMPLE 10: Kinetic resolution on the mixture of (SS + SR) epoxides .
A solution of the mixture of (SS +SR) epoxides (4.50 g, 22.5 mmol) and benzylamine (3.8 mL, 35 mmol) in 2- methyl-2-butanol (38 mL) was mixed at room temperature for 12 hours. At the end of the reaction, the amine (10, SR) formed was filtered under vacuum and dried (1.90 g, 6.30 mmol) . The filtered solution was poured in cyclohexane (250 mL) and the solution thus obtained was washed with 1M NaHS04 (100 mL) and H20 (50 mL x 2) and then concentrated under reduced pressure to obtain 1.30 g
(6.00 mmol) of (SS) epoxide (12).
Kinetic resolution on the mixture of (RS + RR) epoxides was conducted likewise what described in the above example.
EXAMPLE 11: Synthesis of (SSSR) benzyl 1-nebivolol The compound (RS) -2-benzylamino-l- ( 6-fluorochroman- 2-yl (9) , coethanol and the epoxide (12, SS) were dissolved in absolute ethanol (6 mL) and maintained under reflux until disappearance of the starting reagents. At the end of the reaction the mixture was left to reach room temperature and the solvent was removed under reduced pressure.
EXAMPLE 12: Synthesis of (RRRS) d-benzyl nebivolol The compound (SR)-2- benzylamino -l-(6- fluorochroman-2-yl (10), ethanol and the epoxide (11, RR) were treated as in Example 11, to obtain d-benzyl nebivolol .
EXAMPLE 13: Synthesis of d,l-benzyl nebivolol
L-benzyl nebivolol described in example 11 (3.00 g) and d-benzyl nebivolol described in example 12 (3.00 g) were reunited and the mixture thus obtained (6.0 g) was collected again in 2-methyl-2-butanol (36 mL) , heated to dissolution (80°C) and left at room temperature for 24h under light stirring. The obtained solid was filtered, collecting it again with 2-methyl-2-butanol (5 mL) . It was dried on filter. 4.20 g of crystalline mixture having a 99.6% purity were obtained.
EXAMPLE 14 : Synthesis of nebivolol hydrochloride
The compound d, l-benzyl nebivolol (2.0 g, 4.0 mmol) was dissolved in methanol (160 mL) along with 20% (1% b/w) Pd(OH)2/C. The mixture was maintained under stirring, under hydrogen atmosphere. At the end of the reaction the catalyst was filtered on a porous septum, and concentrated HC1 (0.52 mL) was added to the filtrate. The solution was concentrated under reduced pressure and the obtained residue was heat-treated with absolute
ethanol (20 mL) . The obtained solid was filtered and dried under vacuum (1.7 g) .
Claims
1. A process for the preparation of a mixture epoxides (1) , throug the intermediate diol (3) ,
(2) with LiCH2Br, at a temperature lower than -90 °C in an inert solvent, subsequently adding an aqueous means at the same temperature, and thereafter treating the aqueous mixture with a reducing agent to obtain the mixture of the diol (3) ;
2. The process according to claim 1, wherein step (b) comprises the following synthetic steps:
1. treating the mixture of the diol (3) with a mesylating or tosylating agent, and subsequently, by an intramolecular substitution, generating the
mixture of epoxides (1) .
3. The process according to claim 1 or 2, wherein the diols (3) obtained at step (a) are purified by partitioning between a polar organic solvent and an apolar solvent immiscible with each other, the diol thus purified is then subjected to step (b) .
4. The process according to any one of the claims 1 to 3, wherein in step (a) :
the ester (2) is reacted as R isomer or, alternatively, as S isomer, obtaining a mixture of diols (5) comprised of RS + RR isomers
(RS) (RR)
(5) or, alternatively, of a mixture
(SR) (ss) (6) b) treating the mixture of RS + RR diols (5) or, alternatively, the mixture of SR + SS diols (6), with a mesylating or tosylating agent to yield the ,semichiral' mixture of RS + RR epoxides (7)
(RS) (RR)
(8)
5. The process according to any one of the claims 1 to 4, wherein the synthetic step a) is conducted at a temperature comprised between -130°C and -95°C.
6. The process according to claim 5, wherein the temperature is comprised between -105°C and -95°C.
7. The process according to any one of the claims 1 to 6, wherein in synthetic step a) the aqueous solution used for the treatment may be neutral or acidic but anyhow used an amount such as to maintain the environment under alkalinity conditions.
8. The process according to any one of the claims 1 to 7, wherein group R represents an ethyl.
9. The process according to any one of the claims 1 to 8, wherein the organometallic compound LiCIH^Br is generated in situ by adding a BuLi solution to a solution containing the ester (2) and the C¾Br2 in an inert organic solvent at a temperature lower than -90°.
10. The process according to any one of the claims 1 to 9, wherein the reducing agent in synthetic step a) is selected from NaBH4 or LiBH4, preferentially NaBH4.
11. The process according to any one of the claims 3 to 10 wherein, in the diol purification step, the polar organic solvent is selected from methanol, ethanol, acetonitrile, DMF (dimethylformamide) , DMI (dimethylimidazolidinone) , NMP (N-methylpyrrolidone) , and preferentially methanol, and the apolar solvent immiscible with the former is a C5-C10 alkane or a mixture of C5-C10 alkanes, preferentially heptane.
12. The process according to any one of the claims 2 to 11, wherein in step (b) the mixture of the diols is
reacted in an organic solvent selected from dichloromethane, methyl tert-butyl ether, tetrahydrofuran, DMF, DMSO, NMP and DMI, and preferentially DMF, with a base selected from LiH, NaH, KH, tBuOK and preferentially NaH, optionally in the presence of a salt of lithium, potassium or cesium, and subsequently with a mesylating or tosylating agent selected from tosyl chloride (TsCl) , tosyl imidazole and mesyl chloride, and preferentially TsCl.
13. The process according to any one of the claims 2 to 11, wherein, alternatively to what described in claim 12, the mixture of the diols is reacted with a system comprised of a preformed solution in an organic solvent, selected from DMSO/NaH, or of imidazole/NaH and a tosylating agent selected from tosyl chloride (TsCl), tosyl imidazole and preferentially TsCl.
14. The process according to any one of the claims 2 a 11, wherein, alternatively to what described in claims 12 and 13, the mixture of the diols is reacted in an organic solvent non-miscible with water, with a tosylating agent selected from tosyl chloride or tosyl imidazole, preferably tosyl chloride, with 50% NaOH in water, under conditions provided for the Schotten-Baumann reaction .
15. The process according to any one of the claims 2 to 11, wherein, alternatively to what described in claim 12, 13 and 14, the mixture of the diols is reacted in an organic solvent non-miscible with water, and containing an organic base, preferentially diisopropylethylamine, cooled and maintained at a temperature lower than 25°C, preferentially lower than 4°C, with a solution of tosyl chloride in organic solvent, followed by addition of an aqueous NaOH solution.
16. The process comprising all steps according to any one of the claims 1 to 3 and 5 to 15 for the synthesis of nebivolol in the form of racemic mixture of
the two enantiomers [2S [2R [R [R] ] ] ] a, a' - [ imino-bis (methylene)] bis [ 6-fluoro-chroman-2-methanol ] e
[2R[2S [S [S] ] ] ] a, ' -[ imino-bis (methylene)] bis [ 6-fluoro- chroman-2-methanol ] , having the following formulas
NebivoloL (SRRR + RSSS)
comprising the further steps wherein:
a) a mixture of the four SR, RS, RR and SS isomers of the epoxide of formula ( 1 )
( 1 )
is reacted with benzylamine in a solvent represented by a sterically hindered alcohol selected from tert-BuOH, 2-methyl-2-butanol, 2-methyl-2-pentanol, used alone or in mixture with an apolar solvent, preferably cyclohexane, to obtain a mixture of the four compounds 9, 10, 11 and 12, from which the pair 9/10 is separated from the pair 11/12;
b) the amines 9 and 10, in mixture, are reacted with the pair of epoxides 11 and 12, in mixture, to obtain a mixture of four compounds (13, 14, 15 and 16) ;
c) the compounds 13 and 15 (RSSS + SRRR) , in mixture, are separated from 14 and 16 by fractionated crystallization from 2-methyl-2-butanol, and subsequently from an ethyl acetate/cyclohexane mixture,
d) the protecting group benzyl is removed, and the hydrochloride salt is optionally subsequently formed, to obtain the final product Nebivolol or Nebivolol hydrochloride .
17. The process according to claims 4 to 15, for the synthesis of nebivolol, comprising the following steps: a) kinetically resolving the ,semichiral' mixture of epoxides (7), and/or separately the ,semichiral' mixture of epoxides (8) by reacting them with benzylamine in a sterically hindered alcohol selected from tert-BuOH, 2-methyl-2-butanol, 2-methyl-2-pentanol, to obtain the compounds (9) and (11) and/or respectively the compounds (10) and (12) ;
b) reacting the amino alcohol (9) with the epoxide (12) to obtain the 1-benzyl nebivolol (15) and/or the amino alcohol (10) with the epoxide (11) to obtain the d- benzyl nebivolol (13) ;
c) removing the protecting group benzyl with forming of D- and/or L-nebivolol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000418A ITRM20110418A1 (en) | 2011-08-02 | 2011-08-02 | PROCESS FOR THE PREPARATION OF EPOXY WHICH INTERMEDIATES FOR THE SYNTHESIS OF NEBIVOLOL. |
ITRM2011A000418 | 2011-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013018053A1 true WO2013018053A1 (en) | 2013-02-07 |
Family
ID=44675726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/053956 WO2013018053A1 (en) | 2011-08-02 | 2012-08-02 | Process for the preparation of epoxides as intermediates for the synthesis of nebivolol |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITRM20110418A1 (en) |
WO (1) | WO2013018053A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180004810A (en) * | 2015-05-19 | 2018-01-12 | 저장 아우선 파마슈티칼 씨오., 엘티디. | Neviolol synthesis method and intermediates thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0145067A2 (en) | 1983-12-05 | 1985-06-19 | Janssen Pharmaceutica N.V. | Derivatives of 2,2'-iminobisethanol |
US4654362A (en) | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
EP0334429A1 (en) | 1988-03-23 | 1989-09-27 | Janssen Pharmaceutica N.V. | Agents for lowering the blood pressure |
WO2004041805A1 (en) * | 2002-11-06 | 2004-05-21 | EGIS Gyógyszergyár Rt. | NEW PROCESS FOR THE PREPARATION OF RACEMIC ([2S[2R*[R[R*]]]] and ([2R[2S*[S[S*]]]]-(±)- α,α' -[imino-bis(methylene)]bis[6-fluorochroman-2-methanol] AND ITS PURE [2S[2R*[R[R*]& |
WO2008010022A2 (en) | 2005-12-28 | 2008-01-24 | Cimex Pharma Ag | A process for preparation of racemic nebivolol |
WO2008040528A2 (en) | 2006-10-03 | 2008-04-10 | Zach System S.P.A. | Process for preparing nebivolol |
WO2008064827A2 (en) * | 2006-11-27 | 2008-06-05 | Zach System S.P.A. | Process for preparing nebivolol |
WO2010034927A1 (en) | 2008-09-24 | 2010-04-01 | Zach System | Method for preparing nebivolol |
WO2010089764A2 (en) | 2009-01-05 | 2010-08-12 | Msn Laboratories Limited | Improved process for the preparation of nebivolol hydrochloride |
WO2011098474A1 (en) | 2010-02-11 | 2011-08-18 | Menarini International Operations Luxembourg S.A. | Process for the preparation of nebivolol |
-
2011
- 2011-08-02 IT IT000418A patent/ITRM20110418A1/en unknown
-
2012
- 2012-08-02 WO PCT/IB2012/053956 patent/WO2013018053A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0145067A2 (en) | 1983-12-05 | 1985-06-19 | Janssen Pharmaceutica N.V. | Derivatives of 2,2'-iminobisethanol |
US4654362A (en) | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
EP0334429A1 (en) | 1988-03-23 | 1989-09-27 | Janssen Pharmaceutica N.V. | Agents for lowering the blood pressure |
WO2004041805A1 (en) * | 2002-11-06 | 2004-05-21 | EGIS Gyógyszergyár Rt. | NEW PROCESS FOR THE PREPARATION OF RACEMIC ([2S[2R*[R[R*]]]] and ([2R[2S*[S[S*]]]]-(±)- α,α' -[imino-bis(methylene)]bis[6-fluorochroman-2-methanol] AND ITS PURE [2S[2R*[R[R*]& |
WO2008010022A2 (en) | 2005-12-28 | 2008-01-24 | Cimex Pharma Ag | A process for preparation of racemic nebivolol |
WO2008040528A2 (en) | 2006-10-03 | 2008-04-10 | Zach System S.P.A. | Process for preparing nebivolol |
WO2008064827A2 (en) * | 2006-11-27 | 2008-06-05 | Zach System S.P.A. | Process for preparing nebivolol |
WO2010034927A1 (en) | 2008-09-24 | 2010-04-01 | Zach System | Method for preparing nebivolol |
WO2010089764A2 (en) | 2009-01-05 | 2010-08-12 | Msn Laboratories Limited | Improved process for the preparation of nebivolol hydrochloride |
WO2011098474A1 (en) | 2010-02-11 | 2011-08-18 | Menarini International Operations Luxembourg S.A. | Process for the preparation of nebivolol |
Non-Patent Citations (1)
Title |
---|
TETRAHEDRON, vol. 56, 2000, pages 6339 - 6344 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180004810A (en) * | 2015-05-19 | 2018-01-12 | 저장 아우선 파마슈티칼 씨오., 엘티디. | Neviolol synthesis method and intermediates thereof |
JP2018522060A (en) * | 2015-05-19 | 2018-08-09 | チョーチアン オウスン ファーマシューティカル カンパニー リミテッド | Nebivolol synthesis method and intermediate compounds thereof |
US10526304B2 (en) | 2015-05-19 | 2020-01-07 | Zhejiang Ausun Pharmaceutical Co., Ltd. | Nebivolol synthesis method and intermediate compound thereof |
US11142512B2 (en) | 2015-05-19 | 2021-10-12 | Zhejiang Ausun Pharmaceutical Co., Ltd. | Nebivolol synthesis method and intermediate compound thereof |
KR102529680B1 (en) | 2015-05-19 | 2023-05-09 | 저장 아우선 파마슈티칼 씨오., 엘티디. | Method for synthesizing nebivolol and intermediate compounds thereof |
Also Published As
Publication number | Publication date |
---|---|
ITRM20110418A1 (en) | 2013-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5108017B2 (en) | Preparation method of nebivolol | |
JP2019504041A (en) | Chiral spirobiindane skeleton compound and method for producing the same | |
JP5698266B2 (en) | Preparation method of nebivolol | |
KR20130121901A (en) | Process for the preparation of nebivolol | |
EP2265596B1 (en) | Process for preparing nebivolol | |
JP2012503636A (en) | Preparation method of nebivolol | |
WO2013018053A1 (en) | Process for the preparation of epoxides as intermediates for the synthesis of nebivolol | |
CZ294311B6 (en) | Reduction process of prochiral ketone | |
CA2462156A1 (en) | A process for the stereoselective synthesis of 2-hydroxymethyl-chromans | |
RU2735600C2 (en) | Method of producing (r)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridine-1(2h)-yl)methyl]imidazolidine-2,4-dione and an intermediate compound for synthesis thereof | |
US20030100774A1 (en) | Process for synthesis of 2-yl chroman derivatives | |
EP0430808B1 (en) | Dihydropyran derivatives, their processes of preparation and their use | |
WO2014111903A2 (en) | A process for the preparation of 6-fluoro-3,4-dihydro-2h-chromene- 2-carbaldehyde | |
CN109776612A (en) | A kind of synthetic method of phosphachromene derivative | |
EP0441116B1 (en) | Process and intermediates for the manufacture of optically active chroman derivatives | |
JP2002069026A (en) | Method for producing (E) -3-methyl-2-cyclopentadecenone | |
US10633314B2 (en) | Method for the conversion of Abienol to Sclarediol | |
EP1997815B1 (en) | Method for producing flavan derivatives | |
CN117903043A (en) | Preparation method of cis-2-pyridine-2-yl cyclohexanol | |
KR20010099122A (en) | Resolution process for preparing l-muscone or d-muscone | |
JPS5993069A (en) | Preparation of epoxysuccinic acid monoester | |
JPS5929628A (en) | Optically active compound | |
MXPA01010768A (en) | Processes and intermediates for preparing substituted chromanol derivatives | |
CZ86799A3 (en) | Processes for preparing substituted derivatives of chromanol and intermediates for those processes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12761669 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12761669 Country of ref document: EP Kind code of ref document: A1 |